Research Grade Ipilimumab ( 伊匹木单抗 )
- 发布日期： 2020-10-28
- 更新日期： 2025-10-24
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00107
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
477202-00-9
|
| 保质期 |
一年
|
| 抗体名 |
Ipilimumab ( 伊匹木单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
CTLA4/CD152[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号（Catalog No.）
CSD00107
通用名INN
Ipilimumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells.3 CTLA-4 and CD28 are both presented on the surface of T-cells.3 Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
别名(Alternative names)
BMS-734016,MDX-010,MDX-CTLA-4
靶点;物种(Specificity target name;species)
CTLA4/CD152[Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
Ipilimumab (anti-CTLA-4), is a fully humanized IgG1k monoclonal antibody produced by recombinant DNA technology in a CHO mammalian cell expression system, binding with high affinity to the extracellular domain of human (and Cynomolgus monkey) CTLA-4, and acting as an inhibitor of its complex functions. This essentially results in T-cell activation and proliferation, and in lymphocyte infiltration leading to tumor cell death. However, the enhancement of T effector cell function, combined with the inhibition of CD4+ Treg and CD8+ suppressive cell types, are considered essential for mediating the full therapeutic effects of ipilimumab. Ipilimumab can improve ATC proliferation, enhance the BiAb-mediated tumor-specific cytotoxicity, and increase cytokine synthesis, while it attenuates Treg activity as shown by decreased level of IL-10 secretion and reduced Treg population. Ipilimumab and nivolumab treatments could collaboratively enhance effector and memory T cell responses without inappropriately activating naive T cells.
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
分子量(MV)
148000.00 Da
CAS
477202-00-9
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
